AI-Driven Antigen Prediction for Pandemic Preparedness Vaccine Design

Accelerating the timeline between novel pathogen identification and the synthesis of viable vaccine candidates remains a critical bottleneck in global infectious disease control. To resolve structural delays in conventional antigen screening, NEC Corporation, through its biotechnology subsidiary NEC OncoImmunity AS, has joined the Horizon Europe–funded consortium PREPAIR VAC to establish an artificial intelligence–driven vaccine design architecture for emerging viral threats.

Predictive Epitope Selection and Viral Mutation Forecasting
Standard immunological pipelines often depend on empirical screening and reactive antigen synthesis, which can lead to delayed responses and reduced efficacy as pathogens mutate under selective pressure. Designing broadly protective vaccines against rapidly shifting viral families requires identifying conserved immunological targets capable of eliciting durable cellular and humoral immune responses across genetically diverse host populations.

Within the four-year, approximately 6.5-million-euro project starting in September 2026, NEC OncoImmunity operates as the primary initiator for computational antigen prediction. The software platform applies machine learning algorithms to model human leukocyte antigen (HLA) binding dynamics, T-cell receptor interactions, and viral escape mutations. By simulating evolutionary trajectories across pathogen sequences, the system identifies structurally stable, broadly protective epitopes before these variants dominate circulating populations.

Consortium Workflow and Translational Validation Architecture
Coordinated by the European Vaccine Initiative, PREPAIR VAC establishes an integrated translational pipeline connecting in silico discovery to downstream validation. The AI-generated vaccine designs interface directly with specialized consortium partners handling downstream workflows:

Dr. Kaidre Bendjama, Chief Scientific Officer at NEC OncoImmunity, noted that the initiative focuses on applying computational methods to address host and pathogen diversity while anticipating mutations, generating proof-of-concept validation packages across preclinical and translational systems.

Additional Context:
This section details technical specifications and competitive benchmarking not included in the original product announcement

Computational epitope prediction tools historically relied on position-specific scoring matrices and basic neural networks (such as early iterations of NetMHCpan) to predict peptide binding affinity to major histocompatibility complex (MHC) class I and class II molecules. While adequate for linear peptide binding to common HLA alleles, these legacy models frequently mischaracterized complex conformational epitopes and failed to account for dynamic antigen processing mechanisms, including proteasomal cleavage and transporter associated with antigen processing (TAP) efficiency.

Modern structural bioinformatics platforms, including DeepMind's AlphaFold ecosystem and proprietary neural network frameworks developed by organizations such as Moderna and BioNTech, incorporate evolutionary sequence alignments alongside molecular dynamics to predict conformational stability and immune evasion pathways. In pandemic preparedness, benchmark workflows require models capable of multi-allele coverage to ensure population-level protection, as global HLA polymorphisms lead to disparate immune presentations across human cohorts.

Integrating generative predictive modeling into early-stage discovery addresses the empirical trial-and-error cycle of preclinical screening. By narrowing millions of possible genomic sequences to optimized consensus targets, in silico pipelines lower bioprocessing failure rates and support compressed regulatory filing windows in compliance with European Medicines Agency (EMA) emergency validation protocols.

Edited by Natania Lyngdoh, Induportals editor, with AI assistance.

www.nec.com